<DOC>
	<DOC>NCT03098979</DOC>
	<brief_summary>The objective of the study is to find the optimal dose of once daily oral neladenoson bialanate (BAY1067197) when given in addition to appropriate therapy for specific comorbidities.</brief_summary>
	<brief_title>A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Adenosine A1 Receptor Agonists</mesh_term>
	<criteria>Men or women aged 45 years and older Diagnosis of chronic heart failure, NYHA (New York Heart Association) class IIIV, LVEF (left ventricular ejection fraction) â‰¥ 45% and elevated NTproBNP Acute decompensated heart failure within the past 4 weeks Inability to exercise Previous diagnosis of HFrEF (heart failure with reduced ejection fraction) (LVEF &lt; 40%)</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic Heart Failure</keyword>
	<keyword>Heart Failure with Preserved Ejection Fraction</keyword>
</DOC>